Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Child’s Play: Sciele To Boost Pediatric Presence With Alliant Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal worth $122 million gives Sciele products including Orapred and oral suspension of Allegra.
Advertisement

Related Content

Sciele’s Antidrooling Liquid Passes Phase III
Sciele’s Antidrooling Liquid Passes Phase III
Sciele/LifeCycle’s “Meltdose” Fenofibrate Clears FDA
Sciele/LifeCycle’s “Meltdose” Fenofibrate Clears FDA
Sciele Pharma Will Market Clonicel Under Addrenex Deal
Sciele Pharma Will Market Clonicel Under Addrenex Deal
Alliant To Detail Allegra Oral Suspension
Alliant To Detail Allegra Oral Suspension

Topics

Advertisement
UsernamePublicRestriction

Register

PS065951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel